RECELL System Insurance Launches in Japan to Treat High Fever

VALENCIA, Calif. and MELBOURNE, Australia, Sept. 01, 2022 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), an innovative company leading the development and commercialization of first-in-class products. tools and autologous cellular therapy for skin regeneration, announced today that COSMOTEC, an M3 Group Company, has received insurance in Japan for RECELL.® The treatment plan is on fire.

“We are very pleased that Japan’s MHLW (Ministry of Health, Labor and Welfare) has granted marketing approval to the RECELL System at a favorable price that will match the prices in the United States,” said Dr. Mike Perry, Chief Executive Officer of the United States. AVITA Medical. “We look forward to continuing to work with our partner, COSMOTEC, as they launch and promote RECELL in the Japanese market.”

The RECELL System is used to create Spray-On Skin ™ cells using a small amount of patient skin, to treat burn wounds, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used during care alone or in combination with autografts depending on the depth of the burn injury.

“We will use the strength of our strong team to support the successful implementation of RECELL in Japan,” said Mr. Tatsuro Tsutsumi, CEO of COSMOTEC. “By having this product on the market, we hope to help treat burn patients with the goal of returning them to their daily lives as soon as possible.”

On the M3
M3 Inc. is a publicly traded company on the Tokyo Stock Exchange (TYO:2413) with subsidiaries in major markets including the USA, UK, Japan, South Korea, and China. M3 Inc. provides services to healthcare and life science companies. In addition to market research, these services include clinical education, quality medicine promotion, clinical development, recruitment, and clinical recruitment services. M3 Inc. operates in the US, Asia, and Europe with more than 4.5 million doctors worldwide through its websites including,,, and M3 has offices in Tokyo, Washington DC, Fort Washington, PA, Oxford, London, Beijing, and Seoul. Please visit for more information.

More about COSMOTEC
COSMOTEC Co., Ltd., established in 1992, is engaged in the sale and consulting of medical equipment with a focus on cardiac surgery, general surgery and gastroenterology. COSMOTEC has a 98% share of the market for cardiac surgery organizations in Japan. COSMOTEC has offices in Tokyo, Sapporo, Sendai, Nagoya, Osaka, Okayama and Fukuoka throughout Japan. COSMOTEC is a subsidiary of M3, Inc.. Please visit for more information.

History of AVITA Medical, Inc.
AVITA Medical is a regenerative medicine company leading the development and commercialization of devices and autologous cellular therapies for skin regeneration. Image of RECELL® The System’s technology platform, approved by the FDA for the treatment of hyperthermia in adults and children, uses the patient’s own skin to create Spray-On Skin™ cells. Delivered at the point of care, RECELL supports better clinical outcomes with guaranteed cost savings. RECELL is the enabler of a new treatment paradigm and AVITA Medical is leveraging its proven and differentiated capabilities to develop first-of-its-kind treatments for multiple areas, including chronic scar tissue and the transformation of persistent vitiligo lesions.

AVITA Medical’s first product in the US, the RECELL System, was approved by the US Food and Drug Administration (FDA) in September 2018. The RECELL System is approved for the treatment of chronic inflammatory bowel disease in patients 18 years of age or older. combined with meshed autografting for thick-thickness burn wounds in patients and adults. In February 2022, the FDA reviewed and approved the PMA extension for the RECELL Autologous Cell Harvesting Device, an improved version of the RECELL System that aims to provide clinicians with more efficient use and simpler procedures.

The RECELL System is used to prepare Spray-On Skin™ Cells using a small amount of the patient’s own skin, providing a new high-temperature treatment option, and significantly reducing the amount of donor skin needed. The RECELL System is designed to be used during care alone or in combination with autografts depending on the depth of the burn injury. Data from randomized controlled clinical trials conducted in major burn centers in the US and the actual use of more than 15,000 patients worldwide, prove that the RECELL System is a significant improvement over the care of burn patients and provides benefits in clinical outcomes. and save cost. Healthcare professionals should read the INSTRUCTIONS FOR USE – RECELL Autologous Cell Harvesting Device () for detailed information on its use and safety information including contraindications, warnings, and precautions.

In international markets, our products are approved under the RECELL System brand to promote skin healing in a variety of applications including burns, acute wounds, vitiligo, and beauty. The RECELL System is TGA registered in Australia, CE approved in Europe and PMDA approved in Japan. For more information, visit


This press release contains forward-looking statements. These forward-looking statements can often be identified by the use of words such as “expect,” “anticipate,” “intend,” “could,” “could,” “will,” “believe,” “expect,” “look.” forward,” “forecast,” “goal,” “goal,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and use future dates. Forward-looking statements contained in this press release include, but are not limited to, statements regarding, among other things, our ongoing clinical trials and product development activities, the approval of our products, the potential for future growth of our business, and our prospects. to achieve our core business, operational, and financial goals. Forward-looking statements by their nature speak of things that are, by contrast, uncertain. Any forward-looking statement contained in this article contains risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Potential risks and uncertainties include, among other things, the timing and fulfillment of approvals for our products; physician approval, acceptance, and use of our products; failure to obtain the expected profits from the acceptance of our products; the effects of regulatory actions; product credit claims; risks related to international operations and expansion; and other business outcomes, including corporate, financial or political outcomes beyond the company’s control. Investors should not place undue reliance on the information contained herein. Investors are encouraged to read our publicly available documents to discuss these and other risks and uncertainties. The forward-looking statements in this article speak only as of the date of publication, and we are under no obligation to update or revise any of these statements.

This article was approved by the review board of AVITA Medical, Inc.


US Media
Company opinion Sam Brown, Inc.
Christy Curran
Phone +1-615-414-8668

OUS Media
Rudy Michelson
Phone +61 (0)3 9620 3333
Phone +61 (0)411 402 737

Westwick Partners
Caroline Corner
Phone +1-415-202-5678